A novel C-C chemokine receptor 2 antagonist prevents progression of albuminuria and atherosclerosis in mouse models

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 2069-2074

  Okamoto, Masayuki ^a   Fuchigami, Masahiro ^a   Suzuki, Takeshi ^a   Watanabe, Nobuhide ^a  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

Albuminuria; Antagonist; Atherosclerosis; C C chemokine ligand 2; C C chemokine receptor 2

Indexed keywords

1 (1,3 DIMETHYL 1 H PYRAZOLO[3,4 B] PYRIDINE 5 CARBONYL) 3 [4 FLUORO 3 (TRIFLUOROMETHYL)PHENYL]UREA; APOLIPOPROTEIN E; CARBOXYETHYLGERMANIUM SESQUIOXIDE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; TLK 19705; UNCLASSIFIED DRUG;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; MALE; MICROALBUMINURIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT DURATION; TREATMENT RESPONSE;

ALBUMINURIA; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CREATININE; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, TRANSGENIC; PHENYLUREA COMPOUNDS; PYRAZOLES; RECEPTORS, CCR2;

EID: 84869239084     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00528     Document Type: Article

References (47)

1. D'Ambrosio D, Panina-Bordignon P, Sinigaglia F. Chemokine receptors in inflammation: an overview. J. Immunol. Methods, 273, 3-13 (2003).
2. Lukacs NW. Role of chemokines in the pathogenesis of asthma. Nat. Rev. Immunol, 1, 108-116 (2001).
3. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity, 12, 121-127 (2000).
4. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: multiple levels of leukocyte migration control. Trends Immunol., 25, 75-84 (2004).
5. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint disease: the key to inflammation? Ann. Rheum. Dis., 63, 1186-1194 (2004).
6. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med., 354, 610-621 (2006).
7. Bracke KR, Demedts IK, Joos GF, Brusselle GG. CC-chemokine receptors in chronic obstructive pulmonary disease. Inflamm. Allergy Drug Targets, 6, 75-79 (2007).
8. Barlic J, Murphy PM. Chemokine regulation of atherosclerosis. J. Leukoc. Biol., 82, 226-236 (2007).
9. Hamann I, Zipp F, Infante-Duarte C. Therapeutic targeting of chemokine signaling in Multiple Sclerosis. J. Neurol. Sci., 274, 31-38 (2008).
10. Koenen RR, Weber C. Therapeutic targeting of chemokine interactions in atherosclerosis. Nat. Rev. Drug Discov., 9, 141-153 (2010).
11. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol., 7, 327-340 (2011).
12. Dawson J, Miltz W, Mir AK, Wiessner C. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin. Ther. Targets, 7, 35-48 (2003).
13. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res., 29, 313-326 (2009).
14. Kang YS, Cha JJ, Hyun YY, Cha DR. Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments. Expert Opin. Investig. Drugs, 20, 745-756 (2011).
15. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Paritami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A., 87, 5134-5138 (1990).
16. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc. Natl Acad. Sci. U.S.A., 91, 3652-3656 (1994).
17. Haringman JJ, Gerlag DM, Smeets TJM, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum., 54, 2387-2392 (2006).
18. Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum., 58, 1931-1939 (2008).
19. Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin. Ther, Pat, 19, 295-303 (2009).
20. Gilbert J, Lekstrom-Himes J, Donaldson D, Lee Y, Hu M, Xu J, Wyant T, Davidson M; MLN1202 Study Group. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am. J. Cardiol., 107, 906-911 (2011).
21. Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J. Clin. Invest., 103, 73-80 (1999).
22. Panzer U, Thaiss F, Zahner G, Barth P, Reszka M, Reinking RR, Wolf G, Helmchen U, Stahl RA. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int., 59, 1762-1769 (2001).
23. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int., 65, 116-128 (2004).
24. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int., 69, 73-80 (2006).
25. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia, 50, 471-480 (2007).
26. Giunti S, Tesch GH, Pinach S, Burt DJ, Cooper ME, Cavallo-Perin P, Camussi G, Gruden G. Monocyte chemoattractant protein-1 has prosclerotic effects both in a mouse model of experimental diabetes and in vitro in human mesangial cells. Diabetologia, 51, 198-207 (2008).
27. Ninichuk V, Clauss S, Kulkarni O, Schmid H, Segerer S, Radomska E, Eulberg D, Buchner K, Selve N, Klussmann S, Anders HJ. Late onset of Cc12 blockade with the Spiegelmer mNOX-E36-3′PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am. J. Pathol, 172, 628-637 (2008).
28. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, Deferrari G, Gambino R, Vergola D, Pinach S, Perin PC, Camussi G, Gruden G. Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes, 58, 2109-2118 (2009).
29. Kang YS, Lee MH, Song HK, Ko GJ, Kwon OS, Lim TK, Kim SH, Han SY, Han KH, Lee JE, Han JY, Kim HK, Cha DR. CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kidney Int., 78, 883-894 (2010).
30. Sayyed SG, Ryu M, Kulkarni OP, Schmid H, Lichtnekert J, Grüner S, Green L, Mattei P, Hartmann G, Anders HJ. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int., 80, 68-78 (2011).
31. Awad AS, Kinsey GR, Khutsishvili K, Gao T, Bolton WK, Okusa MD. Monocyte/macrophage chemokine receptor CCR2 mediates diabetic renal injury. Am. J. Physiol. Renal Physiol., 301, F1358-F1366 (2011).
32. Tamura Y, Sugimoto M, Murayama T, Ueda Y, Kanamori H, Ono K, Ariyasu H, Akamizu T, Kita T, Yokode M, Arai H. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler. Thromb. Vasc. Biol., 28, 2195-2201 (2008).
33. Yamashita T, Kawashima S, Ozaki M, Namiki M, Inoue N, Hirata K, Yokoyama M. Propagermanium reduces atherosclerosis in apolipoprotein E knockout mice via inhibition of macrophage infiltration. Arterioscler. Thromb. Vasc. Biol., 22, 969-974 (2002).
34. Eto Y, Shimokawa H, Tanaka E, Morishige K, Fuchigami M, Ishiwata Y, Matsushima K, Takeshita A. Long-term treatment with propagermanium suppresses atherosclerosis in WHHL rabbits. J. Cardiovasc. Pharmacol, 41, 171-177 (2003).
35. Shimokawa H, Eto Y, Miyata K, Morishige K, Kandabashi T, Matsushima K, Takeshita A. Propagermanium suppresses macrophage-mediated formation of coronary arteriosclerotic lesions in pigs in vivo. J. Cardiovasc. Pharmacol., 41, 372-380 (2003).
36. Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M, Takeya M, Kuziel WA, Matsushima K, Mukaida N, Yokoyama H. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am. J. Pathol, 165, 237-246 (2004).
37. Furuichi K, Wada T, Iwata Y, Kitagawa K, Kobayashi K, Hashimoto H, Ishiwata Y, Asano M, Wang H, Matsushima K, Takeya M, Kuziel WA, Mukaida N, Yokoyama H. CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J. Am. Soc. Nephrol., 14, 2503-2515 (2003).
38. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, Takahashi T, Abe H, Iehara N, Fukatsu A, Okamoto H, Kita T, Doi T, Arai H. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem. Biophys. Res. Commun., 360, 772-777 (2007).
39. Yokochi S, Hashimoto H, Ishiwata Y, Shimokawa H, Haino M, Terashima Y, Matsushima K. An anti-inflammatory drug, propagermanium, may target GPI-anchored proteins associated with an MCP-1 receptor, CCR2. J. Interferon Cytokine Res., 21, 389-398 (2001).
40. Laborde E, Macsata RW, Meng F, Peterson BT, Robinson L, Schow SR, Simon RJ, Xu H, Baba K, Inagaki H, Ishiwata Y, Jomori T, Matsumoto Y, Miyachi A, Nakamura T, Okamoto M, Handel TM, Bernard CC. Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function. J. Med. Chem., 54, 1667-1681 (2011).
41. Monteclaro FS, Charo IF. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. J. Biol. Chem., 272, 23186-23190 (1997).
42. Mirzadegan T, Diehl F, Ebi B, Bhakta S, Polsky I, McCarley D, Mulkins M, Weatherhead GS, Lapierre JM, Dankwardt J, Morgans D Jr, Wilhelm R, Jarnagin K. Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. J. Biol. Chem., 275, 25562-25571 (2000).
43. -/- mice. Atherosclerosis, 208, 370-375 (2010).
44. -/- mouse: magnetic resonance imaging assessment. Arterioscler. Thromb. Vasc. Biol., 30, 253-259 (2010).
45. -/- mice. Cardiovasc. Drugs Then, 23, 113-120 (2009).
46. Hägg DA, Olson FJ, Kjelldahl J, Jernås M, Thelle DS, Carlsson LM, Fagerberg B, Svensson PA. Expression of chemokine (C-C motif) ligand 18 in human macrophages and atherosclerotic plaques. Atherosclerosis, 204, e15-e20 (2009).
47. Zhao Q. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J. Leukoc. Biol., 88, 41-55 (2010).